• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Arthritis Interception in Patients with Psoriasis Treated with Guselkumab.

作者信息

Zabotti Alen, Giovannini Ivan, McGonagle Dennis, De Vita Salvatore, Stinco Giuseppe, Errichetti Enzo

机构信息

Rheumatology Institute, Department of Medicine, University of Udine, c/o Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy.

Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, UK.

出版信息

Dermatol Ther (Heidelb). 2022 Jan;12(1):5-8. doi: 10.1007/s13555-021-00650-5. Epub 2021 Nov 27.

DOI:10.1007/s13555-021-00650-5
PMID:34837168
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8776915/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e39d/8776915/0e35ce00b7ea/13555_2021_650_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e39d/8776915/0e35ce00b7ea/13555_2021_650_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e39d/8776915/0e35ce00b7ea/13555_2021_650_Fig1_HTML.jpg

相似文献

1
Arthritis Interception in Patients with Psoriasis Treated with Guselkumab.使用古塞库单抗治疗的银屑病患者的关节炎干预
Dermatol Ther (Heidelb). 2022 Jan;12(1):5-8. doi: 10.1007/s13555-021-00650-5. Epub 2021 Nov 27.
2
Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study.古塞库单抗治疗活动性银屑病关节炎患者的疗效和安全性：一项随机、双盲、安慰剂对照、2 期研究。
Lancet. 2018 Jun 2;391(10136):2213-2224. doi: 10.1016/S0140-6736(18)30952-8. Epub 2018 Jun 1.
3
Guselkumab: the First Selective IL-23 Inhibitor for Active Psoriatic Arthritis in Adults.古塞奇尤单抗：首个用于治疗成人活动性银屑病关节炎的选择性 IL-23 抑制剂。
Expert Rev Clin Immunol. 2021 Jan;17(1):5-13. doi: 10.1080/1744666X.2020.1857733. Epub 2020 Dec 7.
4
Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic Arthritis.通过 2 项 Guselkumab 治疗银屑病关节炎的 III 期临床试验 1 年的汇总安全性结果。
J Rheumatol. 2021 Dec;48(12):1815-1823. doi: 10.3899/jrheum.201532. Epub 2021 May 1.
5
Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II Trial.银屑病关节炎的综合疾病活动指标：基于古塞单抗在一项干预性 II 期试验中的疗效比较仪器性能。
Arthritis Care Res (Hoboken). 2020 Nov;72(11):1579-1588. doi: 10.1002/acr.24046.
6
Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial.古塞单抗治疗生物制剂初治或既往接受 TNFα 抑制剂治疗的活动性银屑病关节炎患者（DISCOVER-1）：一项双盲、随机、安慰剂对照的 3 期临床试验。
Lancet. 2020 Apr 4;395(10230):1115-1125. doi: 10.1016/S0140-6736(20)30265-8. Epub 2020 Mar 13.
7
Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study.古塞单抗，一种白细胞介素-23p19 亚单位抑制剂，对中重度银屑病关节炎患者附着点炎和指（趾）炎的影响：一项随机、安慰剂对照、II 期研究的结果。
RMD Open. 2020 Jul;6(2). doi: 10.1136/rmdopen-2020-001217.
8
Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Guselkumab 在生物制剂初治的活动性银屑病关节炎患者中的疗效（DISCOVER-2）：一项双盲、随机、安慰剂对照的 3 期临床试验。
Lancet. 2020 Apr 4;395(10230):1126-1136. doi: 10.1016/S0140-6736(20)30263-4. Epub 2020 Mar 13.
9
Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis.古塞单抗（一种针对 IL-23 的 mAb）可使中重度斑块状银屑病患者获得临床和分子应答。
J Allergy Clin Immunol. 2014 Apr;133(4):1032-40. doi: 10.1016/j.jaci.2014.01.025.
10
Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis.古塞库单抗：一种抗白细胞介素-23 抗体，用于治疗中重度斑块状银屑病。
Eur J Dermatol. 2021 Feb 1;31(1):3-16. doi: 10.1684/ejd.2021.3965.

引用本文的文献

1
Arthralgia and Extraintestinal Manifestations in Crohn's Disease Elevate the Risk of IBD-Related Arthritis over Sacroiliitis.克罗恩病中的关节痛及肠外表现增加了患炎性肠病相关关节炎而非骶髂关节炎的风险。
Rheumatol Ther. 2025 Feb;12(1):99-108. doi: 10.1007/s40744-024-00728-4. Epub 2024 Dec 14.
2
Secukinumab in the Treatment of Psoriasis: A Narrative Review on Early Treatment and Real-World Evidence.司库奇尤单抗治疗银屑病：关于早期治疗及真实世界证据的叙述性综述
Dermatol Ther (Heidelb). 2024 Oct;14(10):2739-2757. doi: 10.1007/s13555-024-01255-4. Epub 2024 Sep 24.
3
Management of psoriatic arthritis: a consensus opinion by expert rheumatologists.

本文引用的文献

1
Predictors, Risk Factors, and Incidence Rates of Psoriatic Arthritis Development in Psoriasis Patients: A Systematic Literature Review and Meta-Analysis.银屑病患者发生银屑病关节炎的预测因素、风险因素及发病率：一项系统文献综述和荟萃分析
Rheumatol Ther. 2021 Dec;8(4):1519-1534. doi: 10.1007/s40744-021-00378-w. Epub 2021 Oct 1.
银屑病关节炎的管理：风湿病专家的共识意见
Front Med (Lausanne). 2023 Nov 30;10:1327931. doi: 10.3389/fmed.2023.1327931. eCollection 2023.
4
Biologics in Prevention of Psoriasis to Psoriatic Arthritis Transition: The Need of Prospective Analyses and Stratification According to Time-Related Risk Factors.生物制剂在预防银屑病向银屑病关节炎转变中的应用：根据时间相关危险因素进行前瞻性分析和分层的必要性。
Dermatol Ther (Heidelb). 2024 Jan;14(1):1-3. doi: 10.1007/s13555-023-01072-1. Epub 2023 Nov 30.
5
Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: limitations and opportunities.银屑病生物免疫治疗与炎症性关节炎发病时间的关系：局限性和机遇。
RMD Open. 2023 Sep;9(3). doi: 10.1136/rmdopen-2023-003166.